Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck Buys Heart Disease Company

July 30, 2007 | A version of this story appeared in Volume 85, Issue 31

Merck & Co. will shell out $350 million to acquire NovaCardia, a privately held firm focused on heart disease drugs. NovaCardia's lead product, KW-3902, is a vasodilator in Phase III trials in patients with congestive heart failure. Merck says the drug will complement its existing heart health franchise, which includes the hypertension drug Cozaar and the cholesterol drugs Zocor, Vytorin, and Zetia. San Diego-based NovaCardia plans to spin off a new company to support the clinical development of K201, a compound to treat atrial fibrillation.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.